Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors

por Haznedaroğlu, İbrahim C.
Publicado 2013

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)

por Haznedaroglu, Ibrahim C.
Publicado 2014

Drug Therapy in the Progressed CML Patient with multi-TKI Failure

por Haznedaroglu, Ibrahim C.
Publicado 2015

Immunogenomic phases of COVID-19 and appropriate clinical management

por Haznedaroglu, Ibrahim C
Publicado 2020

On Being a “Physician Patient” with His Own Experimental Therapeutic Drug

por Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.
Publicado 2018

COVID-19, Renin-Angiotensin System, and Hematopoiesis

por Çiftçiler, Rafiye, Haznedaroğlu, İbrahim C.
Publicado 2020

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia

por Malkan, Umit Y., Haznedaroglu, Ibrahim C.
Publicado 2018

Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases

por Koluman, Ahmet, Akar, Nejat, Haznedaroğlu, İbrahim C.
Publicado 2017

Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia

por Okay, Müfide, Çetik, Sıla, Haznedaroğlu, İbrahim C.
Publicado 2019

The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine

por Okay, Mufide, Ozturk, Yusuf, Haznedaroglu, Ibrahim C.
Publicado 2019

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors

por Haznedaroğlu, İbrahim C., Kuzu, Işınsu, İlhan, Osman
Publicado 2020

A New Candidate as a Hemostatic Agent for Difficult Situations During Variceal Bleeding: Ankaferd Blood Stopper

por Ozaslan, Ersan, Purnak, Tugrul, Yildiz, Ayla, Haznedaroglu, Ibrahim C.
Publicado 2011

Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach

por Koçak, Engin, Çelebier, Mustafa, Haznedaroglu, Ibrahim C., Altınöz, Sacide
Publicado 2019

Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content

por Beyazit, Fatma, Beyazit, Yavuz, Tanoglu, Alpaslan, Haznedaroglu, Ibrahim C.
Publicado 2020

Local Bone Marrow Renin-Angiotensin System and Atherosclerosis

por Beyazit, Yavuz, Purnak, Tugrul, Guven, Gulay Sain, Haznedaroglu, Ibrahim C.
Publicado 2010

Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids

por Koluman, Ahmet, Akar, Nejat, Malkan, Umit Y., Haznedaroglu, Ibrahim C.
Publicado 2016

Platelet Activation in Ocular Behçet’s Patients with Posterior Segment Involvement

por Citirik, Mehmet, Ozdal, Pinar C., Keles, Ali, Haznedaroglu, Ibrahim C.
Publicado 2022

Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)

por Ciftciler, Rafiye, Ciftciler, Ali Erdinc, Malkan, Umit Yavuz, Haznedaroglu, Ibrahim C
Publicado 2020

In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coron...

por Turk, Can, Turk, Seyhan, Temirci, Elif Sena, Malkan, Umit Yavuz, Haznedaroglu, İbrahim C.
Publicado 2020

In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cases

por Kocabeyoglu, Sibel, Mocan, Mehmet C, Haznedaroglu, Ibrahim C, Uner, Aysegul, Uzunosmanoglu, Enes, Irkec, Murat
Publicado 2014